Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function
Open Access
- 27 January 2009
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 9 (2) , 127-136
- https://doi.org/10.1038/tpj.2008.19
Abstract
HMATE1 (human multidrug and toxin compound extrusion-1; encoded by SLC47A1) is thought to have an important function in the renal and hepatic elimination of drugs, endogenous compounds and environmental toxins. The goals of this study were to identify genetic variants of hMATE1 and to determine their effects on hMATE1 transport function. We identified four synonymous and six nonsynonymous, coding region variants in DNA samples from 272 individuals (68 Caucasians, 68 African Americans, 68 Asian Americans and 68 Mexican Americans). The overall prevalence of hMATE1 nonsynonymous variants was relatively low with three singleton variants and three variants having allele frequencies ⩾2% in a specific ethnic group. The nonsynonymous hMATE1 variants were constructed and stably transfected into HEK-293 cells. Uptake studies using four known hMATE1 substrates (paraquat, metformin, tetraethylammonium and oxaliplatin) were performed in cells transfected with hMATE1 reference or variants. We found that two singleton variants, G64D and V480M, produced a complete loss of function for all four tested substrates whereas three polymorphic variants (allele frequencies ⩾2%), L125F, V338I and C497S, significantly altered the transport function in a substrate-dependent manner. Confocal microscopy studies were consistent with functional studies suggesting that the altered function of the variants was due to altered localization to the plasma membrane. These data suggest that nonsynonymous variants in hMATE1 may alter drug disposition and ultimately affect clinical drug response.Keywords
This publication has 33 references indexed in Scilit:
- Thermodynamic scaling behavior in genechipsBMC Bioinformatics, 2009
- Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin PharmacokineticsClinical Pharmacology & Therapeutics, 2007
- Explaining differences in saturation levels for Affymetrix GeneChip® arraysNucleic Acids Research, 2007
- Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJournal of Clinical Investigation, 2007
- Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)The Journal of Pharmacology and Experimental Therapeutics, 2006
- Physical-Chemistry-Based Analysis of Affymetrix Microarray DataThe Journal of Physical Chemistry B, 2006
- Organic Cation Transporters Are Determinants of Oxaliplatin CytotoxicityCancer Research, 2006
- Identification and Functional Characterization of a New Human Kidney–Specific H+/Organic Cation Antiporter, Kidney-Specific Multidrug and Toxin Extrusion 2Journal of the American Society of Nephrology, 2006
- Functional and Genetic Diversity in the Concentrative Nucleoside Transporter, CNT1, in Human PopulationsMolecular Pharmacology, 2004
- Thermodynamic Parameters To Predict Stability of RNA/DNA Hybrid DuplexesBiochemistry, 1995